L3VLUP
ProSign in

VYGR in the 13F filings

Voyager Therapeutics Inc · CUSIP 92915B106

Sector · Pharmaceuticals and biotechnologyTheme · Biological productsTheme · Healthcare: biopharma and medtech· L3VLUP-defined
Quarter
Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022
Quarter end
30 Jun 2023
the date the book describes
Filed
15 Aug 2023
latest of these filings; the earliest 7 Aug 2023
Managers listing it
3
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q1 2023 and Q2 2023; 3 listed it in both
Shares listed
2,033,664
combined, among listed positions
Reported value
$23m
combined, at the quarter end

Managers listing VYGR in Q2 2023

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q1 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

3 of 3 holders

ActionFiling
Farallon Capital Management LLC1,292,000$15m0.07%Added+495,00014 Aug 2023 (the filing on sec.gov)
Acadian Asset Management LLC719,659$8.2munder 0.1%Trimmed-22,6967 Aug 2023 (the filing on sec.gov)
Caxton Associates LLP22,005$252kunder 0.1%Trimmed-14,55915 Aug 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

Q1 2023 to Q2 2023, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
3 in Q3 2023 to 1 in Q2 2025

Tracked managers listing it, at least.

01234201820192022202320242025
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
VYGR by quarter
QuarterHoldersReported valueBuyersSellers
Q3 20172$4.8mn.a.n.a.
Q4 20172$14mn.a.n.a.
Q1 20182$20mn.a.n.a.
Q2 20182$17mn.a.n.a.
Q3 20182$17mn.a.n.a.
Q4 20181$8.5mn.a.n.a.
Q1 20191$19mn.a.n.a.
Q2 20191$20mn.a.n.a.
Q2 20201$444kn.a.n.a.
Q3 20201$479kn.a.n.a.
Q4 20201$396kn.a.n.a.
Q1 20221$1.0mn.a.n.a.
Q2 20221$807kn.a.n.a.
Q3 20221$809kn.a.n.a.
Q4 20221$651kn.a.n.a.
Q1 20233$12mn.a.n.a.
Q2 20233$23mn.a.n.a.
Q3 20233$15mn.a.n.a.
Q4 20232$11m01
Q1 20243$25m30
Q2 20244$21m11
Q3 20241$13m00
Q4 20241$15m10
Q1 20251$8.7m00
Q2 20251$2.2m01

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

VYGR and GILD →VYGR and AMGN →VYGR and ARGX →Choose a stock to compare with VYGR →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own VYGR, latest filings →Back to the 13F Explorer →